Premature Ejaculation Treatment Market to Grow by USD 1.46 Billion (2024-2028), High Efficacy of Off-Label Drugs Driving Growth, AI-Powered Report - Technavio
NEW YORK, Dec. 13, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The global premature ejaculation treatment market size is estimated to grow by USD 1.46 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 8.78% during the forecast period. High efficacy of off-label premature ejaculation drugs is driving market growth, with a trend towards advent of nanotechnology in premature ejaculation treatment drugs. However, side effects associated with premature ejaculation treatment drugs poses a challenge. Key market players include A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Eli Lilly and Co., Futura Medical plc, GlaxoSmithKline Plc, Johnson and Johnson, LloydsPharmacy, Morari Inc., NeuroHealing Pharmaceuticals Inc., Niksan Pharmaceutical, Pfizer Inc., Plethora Solutions Ltd., Prinston Pharmaceutical Inc., Ralington Pharma LLP, Sunrise Remedies Pvt. Ltd., Tabuk Pharmaceuticals, Veru Inc., and VIVUS LLC.
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF
Premature Ejaculation Treatment Market Scope
Report Coverage
Details
Base year 2023
Historic period
2018 - 2022
Forecast period
2024-2028
Growth momentum & CAGR Accelerate at a CAGR of 8.78%
Market growth 2024-2028
USD 1459.85 million
Market structure
Fragmented
YoY growth 2022-2023 (%) 7.34
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market
contribution North America at 38%
Key countries
US, Italy, UK, China, and India
A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd.,
Amneal Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Eli Lilly and Co., Futura Medical plc, GlaxoSmithKline
Plc, Johnson and Johnson, LloydsPharmacy, Morari Inc., NeuroHealing Pharmaceuticals Inc., Niksan Pharmaceutical,
Pfizer Inc., Plethora Solutions Ltd., Prinston Pharmaceutical Inc., Ralington Pharma LLP, Sunrise Remedies Pvt.
Key companies profiled Ltd., Tabuk Pharmaceuticals, Veru Inc., and VIVUS LLC
Market Driver
The Premature Ejaculation (PE) treatment market is witnessing significant growth due to the increasing prevalence of PE, also known as rapid or early ejaculation. PE affects individuals during sexual intercourse, leading to incapability to control ejaculation, causing distress and dissatisfaction. PE can be lifelong or acquired, with psychological and biological factors contributing, including early sexual experiences, sexual abuse, poor body image, depression, anxiety, hormone levels, inherited traits, inflammation, and infection. Pharmaceutical companies are launching new treatments, such as Promescent, a topical anesthetic, and Zertane, a local anesthetic spray for the glans. Strategic collaborations and approvals, such as those by Kaiser Permanente for Dapoxetine, are driving market growth. Clinical trials for Tramadol hydrochloride and Westoxeti are underway. Alternative treatment methods, such as Prolong, a FDA-approved device, and behavioral therapies like Fortacin spray, are gaining popularity. However, limitations include travel restrictions, resources, and shortages due to the ongoing pandemic. Telemedicine and digital health platforms offer potential solutions for accessing treatments and interventions. Combination therapies, including medications and behavioral therapies, are also being explored. Erectile dysfunction, a related sexual health issue, is also driving market growth, with companies like Eli Lilly, GlaxoSmithKline, Bayer, Menarini, Teva, Sunrise Pharma, Torrent Pharma, and Vivus offering various treatments. Side effects, such as nausea, dizziness, headache, diarrhea, somnolence, fatigue, and insomnia, are limitations to consider.
Nanotechnology, introduced in the 1980s, offers innovative solutions for developing drug delivery systems in medicine. In the premature ejaculation treatment market, PDE-5 inhibitors like tadalafil, sildenafil, and vardenafil are commonly used off-label due to their ability to inhibit the PDE-5 isoenzyme. These drugs, however, have poor aqueous solubility, leading to low bioavailability and systemic side effects such as facial flushing, headache, nasal congestion, and dyspepsia. To address these challenges, nanotechnology-based drug delivery systems are being explored for improved efficacy and reduced side effects in the treatment of premature ejaculation.
Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!
Market Challenges
-- The Premature Ejaculation (PE) treatment market faces several challenges
in addressing this common sexual health issue. PE, also known as rapid
or early ejaculation, can impact an individual's capability to maintain
satisfactory sexual intercourse. The causes of PE can be psychological
or biological, including factors like early sexual experiences, sexual
abuse, poor body image, depression, anxiety, hormone levels, inherited
traits, inflammation, and infection. PE can be lifelong or acquired.
Pharmaceutical companies, such as Eli Lilly, GlaxoSmithKline, Bayer,
Menarini, Teva, Sunrise Pharma, Torrent Pharma, and Vivus, have launched
various PE treatments, including medications like Dapoxetine and
Westoxeti. Strategic collaborations and clinical trials are ongoing for
new diagnostic tools and combination therapies. However, challenges
include travel restrictions, resources, and shortages due to the ongoing
pandemic. Telemedicine and digital health platforms offer potential
solutions for access to medical assistance. Behavioral techniques,
psychological counseling, and lifestyle modifications are alternative
treatment methods. Local anesthetics like Fortacin can be used to
desensitize the glans for longer intercourse. Limitations include side
effects like nausea, dizziness, headache, diarrhea, somnolence, fatigue,
and insomnia. The FDA has approved a device for PE treatment, and
analgesics can be used to manage sensitivity and enhance sexual pleasure
for both partners. Overall, addressing PE requires a multifaceted
approach, combining pharmaceutical treatments, behavioral therapies, and
interventions.
-- The premature ejaculation treatment market offers various options,
including off-label use of PDE5 inhibitors. These drugs target the PDE5
enzyme in the corpus cavernosum, enhancing erectile function. However,
they carry risks such as prolonged erections and priapism, limiting
their suitability for some users. The market requires innovative
solutions to address these side effects and improve treatment efficacy.
Other therapeutic approaches, like behavioral techniques and counseling,
may offer safer alternatives. Collaborative efforts among researchers,
healthcare providers, and industry can lead to advancements in the
field, ultimately benefiting those seeking effective and safe premature
ejaculation treatments.
Discover how AI is revolutionizing market trends- Get your access now!
Segment Overview
This premature ejaculation treatment market report extensively covers market segmentation by
1. Route Of Administration
-- 1.1 Oral
-- 1.2 Topical
2. Drug Class
-- 2.1 SSRIs
-- 2.2 PDE5 inhibitors
-- 2.3 Amide anesthetics
-- 2.4 Others
3. Geography
-- 3.1 North America
-- 3.2 Europe
-- 3.3 Asia
-- 3.4 Rest of World (ROW)
Research Analysis
Premature ejaculation (PE), also known as rapid or early ejaculation, is a common sexual health issue that affects individuals during sexual intercourse, leading to incapability to delay ejaculation for a desired length of time. This condition can cause distress and frustration for both partners, impacting sexual pleasure and satisfaction. PE can be classified as lifelong or acquired, depending on when it first began. Diagnostic methods include self-reporting and clinical assessments. Medical assistance may include behavioral techniques, such as the stop-start method or squeeze technique, as well as medications like Dapoxetine and Westoxeti, which work by increasing the time before ejaculation. These medications have a relatively short half-life and may cause side effects such as nausea. Planning and communication with partners are also essential in managing PE. Travel restrictions due to the pandemic have made it challenging for some individuals to access medical assistance, but telemedicine and online resources offer alternative solutions.
Market Research Overview
Premature ejaculation (PE), also known as rapid or early ejaculation, is a common sexual health issue that affects individuals during sexual intercourse, resulting in incapability to delay ejaculation for a desired length of time. PE can be classified as lifelong or acquired, depending on whether it has been present since the first sexual encounter or developed later. Both psychological and biological factors contribute to PE. Psychological factors include anxiety, depression, poor body image, and sexual abuse. Biological factors include hormone levels, inherited traits, inflammation, infection, prostate issues, and urethra problems. Various treatments are available for PE, including pharmaceutical treatments like Dapoxetine and Westoxeti, which work by delaying ejaculation, and local anesthetics like Fortacin spray, which desensitize the glans. Behavioral techniques, psychological counseling, and lifestyle modifications are also effective. New launches and approvals in the PE treatment market include Promescent, a topical numbing agent, and Zertane, a new drug under development. Clinical trials are ongoing for Tramadol hydrochloride and other combination therapies. Alternative treatment methods include Prolong, a FDA-approved device, and digital health platforms offering telemedicine consultations. However, travel restrictions, resources, and shortages may impact access to medical assistance. Erectile dysfunction (ED) and PE are related conditions, and PE affects approximately 30% of men at some point in their lives. PE can cause distress and negatively impact sexual pleasure and relationships. Side effects of PE treatments include nausea, dizziness, headache, diarrhea, somnolence, fatigue, and insomnia. It is essential to consult a healthcare professional for proper diagnosis and treatment planning.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
-- Route Of Administration
-- Oral
-- Topical
-- Drug Class
-- SSRIs
-- PDE5 Inhibitors
-- Amide Anesthetics
-- Others
-- Geography
-- North America
-- Europe
-- Asia
-- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/premature-ejaculation-treatment-market-to-grow-by-usd-1-46-billion-2024-2028-high-efficacy-of-off-label-drugs-driving-growth-ai-powered-report---technavio-302330732.html
SOURCE Infiniti Research, Inc.
